# (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

> **NCT05923502** · — · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Follicular Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Richter Syndrome
- Marginal Zone Lymphoma
- Peripheral T Cell Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT05923502
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923502, "(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05923502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*